Navigation Links
TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/10/2007

Final Data from Pivotal Study Presented at 49th American Society of

Hematology Meeting

FRAZER, Pa., Dec. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a pivotal study of patients with indolent non-Hodgkin's lymphoma (NHL), whose disease has progressed during or following treatment with rituximab, TREANDA (bendamustine HCl) induced a high rate of response. TREANDA(R) is a novel investigational chemotherapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment. The final data from this multicenter study were presented at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA [Poster # 505-I; Abstract #1351].

"The high response rate in this study suggest that bendamustine could offer substantial periods of remission to patients with indolent NHL whose cancer is progressing after treatment with rituximab," said Brad Kahl, MD, Associate Professor, Director Lymphoma Service, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, and the lead investigator of this study. "Because many patients with NHL eventually become resistant to treatment with rituximab and other therapies, new treatments are always required."

In this pivotal study of 100 patients with indolent NHL whose disease has progressed during or following treatment with rituximab, or a rituximab- containing regimen, as assessed by an independent radiological committee, 75 patients had a response. Of those patients who responded to treatment, 14 had a complete response and three had an unconfirmed complete response. The median duration of response was 9.2 months. Bendamustine demonstrated a manageable tolerability profile. As would be expected of a chemothera
'/>"/>

SOURCE Cephalon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
11. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  STAAR Surgical Company (NASDAQ: STAA ) ... delivery systems for the eye, today announced that management will ... New York Palace Hotel on Wednesday, September 3 at 7:15 ... President and CEO will offer a general overview of the ... be joined by Steve Brown , CFO, and ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic Biologics, ... anti-infective biologic and drug candidates targeting specific pathogens ... Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation ... cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary oral ... difficile ( C. difficile ) infections. ...
(Date:8/28/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... trials evaluating the use of collagenase clostridium histolyticum (CCH) for ... with a palpable cord will be presented at the upcoming ... Surgery of the Hand (ASSH) being held in ... (CCH) is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:STAAR Surgical To Present At The Baird 2014 Health Care Conference 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
... Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or ... assembly, marketing and sale of medical devices and ... plans to release its financial results for the ... 31, 2011 on Monday, March 19, 2012, after the stock ...
... Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, ... Operating Officer of Aptuit LLC. Following the recent sale ... has been promoted from his previous position at Aptuit ... Needleman is responsible for all day-to-day operations of the ...
Cached Medicine Technology:Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3Aptuit LLC Names Stuart E. Needleman as President and Chief Operating Officer 2
(Date:8/28/2014)... (PRWEB) August 28, 2014 Edvance360 ... the top ten tools for online teaching, as well ... for Best Course or Learning Management System, announced that ... Academy, Typewell, Dialysis Treatment Center of America, Metis Leadership ... and HMG Plus, to the user community. , ...
(Date:8/28/2014)... 2014 Every year, cataracts affect over 22 ... the leading cause of blindness in the world. Characterized by ... the iris, cataracts are estimated to affect an additional 30 ... aging population. Cataracts are just one of the many conditions ... Tracy of Carlsbad Eye Care screens patients for a number ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Labor Day ... the beach and those last glorious glimpses of summer. ... patients are planning on spending their long weekend recovering ... Sadati, a board certified facial plastic and reconstructive surgeon ... patients have taken advantage of their holiday weekends to ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Atlantic Information ... of the latest addition to its Management Insight Series, ... a Major Patient Privacy/Security Risk . The new report ... manage the risks associated with portable electronic devices, and ... federal requirements. , With expert advice on how to ...
(Date:8/28/2014)... 2014 In the healthcare industry, there ... struggle with: How can the overall quality of patient ... of the healthcare industry tackles this question, and has ... job satisfaction and the quality of patient care. ... in “ Organizational Factors related to Improving Quality of ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Cataract Awareness Month an Opportunity to Focus on Vision Care and Ocular Health 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 3Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 4Health News:New Report Offers Best Practices for Avoiding the Patient Privacy/Security Risks Posed by Mobile Devices 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4
... July 7 HealthSouth,Corporation (NYSE: HLS ) ... to acquire a 30-bed inpatient rehabilitation unit at ... is currently owned by Columbia,Medical Center of Arlington ... operations will relocate to HealthSouth Rehabilitation,Hospital of Arlington., ...
... recycling benefits our planet; and now new research suggests ... cancer. Scientists at Stanford University have identified a molecule ... cells. The research, published by Cell Press in the ... , may drive treatment strategies for cancer in an ...
... and geographic boundaries are some of the challenges that ... for a possible influenza pandemic, according to a new ... who are leading planning efforts for an influenza outbreak ... defined by political lines," said George Avery, an assistant ...
... Pa., July 7 Digestive Care, Inc. (DCI),announced today ... New Drug,Application ("NDA") for PANCRECARB(R) (pancrelipase), used in the ... and Drug,Administration ("FDA"). The FDA has granted the product ... used to treat EPI for over,a decade and we ...
... Satisfaction Rate 94% - 100%, ARLINGTON HEIGHTS, ... after an elective mastectomy are satisfied with,their decision, ... do it,again, reports a study in July,s Plastic ... American Society of Plastic Surgeons,(ASPS). In addition, breast ...
... Ill. Women who have breast reconstruction after an ... complication rates and 98 percent would do it again, ... Surgery , the official medical journal of the American ... reconstruction after preventive mastectomy was as safe as or ...
Cached Medicine News:Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 2Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 3Health News:Can recycling be used to treat cancer? 2Health News:Political borders, health-care issues complicate pandemic planning 2Health News:Political borders, health-care issues complicate pandemic planning 3Health News:Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase) 2Health News:98% of Elective Mastectomy Patients Would Have Reconstruction Again, Says ASPS Study 2Health News:98 percent of elective mastectomy patients would have reconstruction again, says ASPS study 2
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... the ease and comfort you've come to expect ... in clinical trials agreed that the BD Lancet ... settings allow you to choose the best lancet ... lancets, the device also helps eliminate the "vibrations" ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
Medicine Products: